

GOTO et al.  
Preliminary Amendment

said cell is an animal cell.

4. A preventive and/or therapeutic agent for obesity according to claim 1 which is administered to human beings and animals.

5. A preventive and/or therapeutic agent for obesity according to claim 1 in the form of a pharmaceutical composition.

6. A preventive and/or therapeutic agent for obesity according to claim 5 wherein said pharmaceutical composition is formulated for oral or parenteral administration.

7. A preventive and/or therapeutic agent for obesity according to claim 5 wherein said pharmaceutical composition is selected from the group consisting of compositions for injection, compositions for dripping, suppositories, nasal agents, sublingual agents and percutaneous absorption agents.

8. A preventive and/or therapeutic agent for obesity according to claim 5 wherein said pharmaceutical composition comprises pharmaceutically acceptable carriers, excipients, stabilizers, coloring matters, or surfactants.

9. A preventive and/or therapeutic agent for obesity according to claim 5 wherein said pharmaceutical composition is a composition formulated for injection comprising a pharmacologically effective amount of stanniocalcin and at least one pharmaceutically acceptable excipient and/or activator.

10. A preventive and/or therapeutic agent for obesity according to claim 9 wherein said excipient and/or activator is one or more of amino acids, human serum

GOTO et al.  
Preliminary Amendment

albumin, sugars and/or cellulose derivatives.

11. A preventive and/or therapeutic agent for obesity according to claim 1 which is administered at a daily dose of 10  $\mu$ g to 10 mg/kg body weight.

12. A preventive and/or therapeutic agent for obesity according to claim 6 which is administered intravenously.

13. A method for treating or preventing obesity which comprises administering to humans or animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

14. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered orally or parenterally.

15. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is in a form selected from the group consisting of compositions for injection, compositions for dripping, suppositories, nasal agents, sublingual agents and percutaneous absorption agents.

16. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition further comprises pharmaceutically acceptable carriers, excipients, stabilizers, coloring matters, or surfactants.

17. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is a composition formulated for injection comprising a pharmacologically effective amount of stanniocalcin and at least one pharmaceutically

GOTO et al.  
Preliminary Amendment

acceptable excipient and/or activator.

18. A method for treating or preventing obesity according to claim 17 wherein said excipient and/or activator comprise amino acids, human serum albumin, sugars, and/or cellulose derivatives.

19. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered at a daily dose of 10  $\mu$ g to 10 mg/kg body weight.

20. A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered intravenously.